Ihor Vynnychenko
0000-0002-2339-6509
Publication & Citation Trends
Publications
0 total
Five-Year Survival Outcomes With Atezolizumab After Chemotherapy in Resected Stage IB-IIIA Non-Small Cell Lung Cancer (IMpower010): An Open-Label, Randomized, Phase III Trial.
Cited by 21
Semantic Scholar
COMPARATIVE ANALYSIS OF BONE HEALING UNDER PHYSIOLOGICAL AND TRACE ELEMENT OVERLOAD CONDITIONS IN SENILE RATS
Cited by 0
Semantic Scholar
IMpower010: Genomic profiling and clinical outcomes with adjuvant atezolizumab in early-stage non-small cell lung cancer (eNSCLC).
Cited by 1
Semantic Scholar
Pembrolizumab plus axitinib versus sunitinib for advanced clear cell renal cell carcinoma: 5-year survival and biomarker analyses of the phase 3 KEYNOTE-426 trial
Cited by 21
Semantic Scholar
Novel Combinations of Immunotherapies or DNA Damage Repair Inhibitors in Platinum-Refractory Extensive-Stage Small Cell Lung Cancer: The Phase II BALTIC Study OA
Cited by 7
Semantic Scholar
IMpower010: Final disease-free survival (DFS) and second overall survival (OS) interim results after ≥5 years of follow up of a phase III study of adjuvant atezolizumab vs best supportive care in resected stage IB-IIIA non-small cell lung cancer (NSCLC).
Cited by 14
Semantic Scholar
KEYNOTE‐033: Randomized phase 3 study of pembrolizumab vs docetaxel in previously treated, PD‐L1‐positive, advanced NSCLC OA
Cited by 17
Semantic Scholar
Research Topics
Cancer Immunotherapy and Biomarkers
(23)
Lung Cancer Treatments and Mutations
(23)
Lung Cancer Research Studies
(17)
Gastric Cancer Management and Outcomes
(15)
Renal cell carcinoma treatment
(14)
Affiliations
Sumy State University
National Cancer Centre Japan
Kyiv City Clinical Oncology Center
The Maria Sklodowska-Curie National Research Institute of Oncology
Moscow City Oncology Hospital №62